



Universiteit  
Leiden  
The Netherlands

## Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

Groen, R.A.L. de; Eijk, R. van; Bohringer, S.; Wezel, T. van; Raghoo, R.; Ruano, D.; ... ; Vermaat, J.S.P.

### Citation

Groen, R. A. L. de, Eijk, R. van, Bohringer, S., Wezel, T. van, Raghoo, R., Ruano, D., ... Vermaat, J. S. P. (2021). Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. *Blood Advances*, 5(19), 3760-3775. doi:10.1182/bloodadvances.2021005215

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3263762>

**Note:** To cite this publication please use the final published version (if applicable).

# Frequent mutated *B2M*, *EZH2*, *IRF8*, and *TNFRSF14* in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

Ruben A.L. de Groen,<sup>1</sup> Ronald van Eijk,<sup>2</sup> Stefan Böhringer,<sup>3</sup> Tom van Wezel,<sup>2</sup> Richard Raghoo,<sup>4</sup> Dina Ruano,<sup>2</sup> Patty M. Jansen,<sup>2</sup> Inge Briaire-de Bruijn,<sup>2</sup> Fleur A. de Groot,<sup>1</sup> Karin Kleiverda,<sup>2</sup> Liane te Boome,<sup>5</sup> Valeska Terpstra,<sup>6</sup> Henriette Levenga,<sup>7</sup> Alina Nicolae,<sup>8</sup> Eduardus F.M. Posthuma,<sup>9</sup> Isabelle Focke-Snieders,<sup>10</sup> Lizan Hardi,<sup>11</sup> Wietske C.E. den Hartog,<sup>12</sup> Lara H. Bohmer,<sup>13</sup> Pancras C.W. Hogendoorn,<sup>2</sup> Anke van den Berg,<sup>14</sup> Arjan Diepstra,<sup>14</sup> Marcel Nijland,<sup>15</sup> Pieternella J. Lugtenburg,<sup>16</sup> Marie José Kersten,<sup>17,18,19</sup> Steven T. Pals,<sup>17,19,20</sup> Hendrik Veelken,<sup>1</sup> Judith V.M.G. Bovée,<sup>2</sup> Arjen H.G. Cleven,<sup>2</sup> and Joost S.P. Vermaat<sup>1</sup>

<sup>1</sup>Department of Hematology, <sup>2</sup>Department of Pathology, <sup>3</sup>Department of Biomedical Data Sciences, and <sup>4</sup>Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands; <sup>5</sup>Department of Internal Medicine, and <sup>6</sup>Department of Pathology, Haaglanden Medical Center, The Hague, The Netherlands; <sup>7</sup>Department of Internal Medicine and <sup>8</sup>Department of Pathology, Groene Hart Hospital, Gouda, The Netherlands; <sup>9</sup>Department of Internal Medicine, and <sup>10</sup>Department of Pathology, Reinier de Graaf Hospital, Delft, The Netherlands; <sup>11</sup>Department of Hematology and <sup>12</sup>Department of Pathology, Alrijne Hospital, Leiderdorp, The Netherlands; <sup>13</sup>Department of Hematology, Haga Hospital, The Hague, The Netherlands; <sup>14</sup>Department of Pathology and Medical Biology, and <sup>15</sup>Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; <sup>16</sup>Department of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands; <sup>17</sup>Lymphoma and Myeloma Center Amsterdam-LYMMCARE, Amsterdam, The Netherlands; <sup>18</sup>Department of Hematology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands; <sup>19</sup>Cancer Center Amsterdam, Amsterdam, The Netherlands; and <sup>20</sup>Department of Pathology, Amsterdam University Medical Centers, University of Amsterdam, The Netherlands

## Key Points

- PB-DLBCL is characterized by a GCB phenotype, a centrocyte-like GEP pattern, GCB-associated mutational profile, and favorable prognosis.
- These features indicate PB-DLBCL as a distinct extranodal DLBCL entity, and its specific mutations offer potential for targeted therapies.

Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal lymphoma subtype. This retrospective study elucidates the currently unknown genetic background of a large clinically well-annotated cohort of DLBCL with osseous localizations (O-DLBCL), including PB-DLBCL. A total of 103 patients with O-DLBCL were included and compared with 63 (extra)nodal non-osseous (NO)-DLBCLs with germinal center B-cell phenotype (NO-DLBCL-GCB). Cell-of-origin was determined by immunohistochemistry and gene-expression profiling (GEP) using (extended)-NanoString/Lymph2Cx analysis. Mutational profiles were identified with targeted next-generation deep sequencing, including 52 B-cell lymphoma-relevant genes. O-DLBCLs, including 34 PB-DLBCLs, were predominantly classified as GCB phenotype based on immunohistochemistry (74%) and NanoString analysis (88%). Unsupervised hierarchical clustering of an extended-NanoString/Lymph2Cx revealed significantly different GEP clusters for PB-DLBCL as opposed to NO-DLBCL-GCB ( $P < .001$ ). Expression levels of 23 genes of 2 different targeted GEP panels indicated a centrocyte-like phenotype for PB-DLBCL, whereas NO-DLBCL-GCB exhibited a centroblast-like constitution. PB-DLBCL had significantly more frequent mutations in four GCB-associated genes (ie, *B2M*, *EZH2*, *IRF8*, *TNFRSF14*) compared with NO-DLBCL-GCB ( $P = .031$ ,  $P = .010$ ,  $P = .047$ , and  $P = .003$ , respectively). PB-DLBCL, with its corresponding specific mutational profile, was significantly associated with a superior survival compared with equivalent Ann Arbor limited-stage I/II NO-DLBCL-GCB ( $P = .016$ ). This study is the first to show that PB-DLBCL is characterized by a GCB phenotype, with a centrocyte-like GEP pattern and a GCB-associated mutational profile (both involved in immune surveillance) and a favorable prognosis. These novel biology-associated features provide evidence that PB-DLBCL represents a distinct extranodal DLBCL entity, and its specific mutational landscape offers potential for targeted therapies (eg, *EZH2* inhibitors).

Submitted 10 May 2021; accepted 13 May 2021; prepublished online on *Blood Advances* First Edition 3 September 2021; final version published online 1 October 2021. DOI 10.1182/bloodadvances.2021005215.

The gene expression profiling data reported in this article have been deposited in the Gene Expression Omnibus database (accession number GSE176126).

The full-text version of this article contains a data supplement.

© 2021 by The American Society of Hematology

## Introduction

The World Health Organization (WHO) Classification of Soft Tissue and Bone recognizes primary bone lymphoma as a specific lymphoma entity, which is primarily represented by diffuse large B-cell lymphoma (DLBCL).<sup>1</sup> Primary bone DLBCL (PB-DLBCL) is a rare DLBCL subtype, with a relative young median age at diagnosis (55 years)<sup>2</sup> and a favorable 5-year overall survival (mean OS, 82%).<sup>2-9</sup> Most patients present with symptoms of pain, bone fractures, localized swelling, or suspected periprosthetic joint infection.<sup>10-13</sup> Patients' physical performance can be affected because weight-bearing bones are commonly involved (eg, femur, spine, pelvis).<sup>2,6,13</sup>

Between studies, reported clinical characteristics and survival rates are diverse due to a lack of strict (anatomical) definitions and consequent proper classification of DLBCL with osseous involvement (O-DLBCL). As such, the WHO classification<sup>1</sup> and Messina et al<sup>2</sup> distinguish 3 different subentities: PB-DLBCL, with a single bone lesion with or without regional involvement of lymph nodes; polyostotic-DLBCL, with multifocal disease in a single bone or multiple affected bones only; and disseminated-DLBCL, with  $\geq 1$  bone lesion(s) and  $\geq 1$  (extra) nodal localization(s). These O-DLBCL subentities illustrate patient outcomes, with a superior survival for PB-DLBCL and polyostotic-DLBCL compared with that for disseminated-DLBCL.

Only a few small retrospective cohort studies have investigated the clinicopathologic characteristics of O-DLBCL. Examining cell-of-origin (COO) with immunohistochemistry (IHC) by using the Hans algorithm,<sup>14</sup> these studies identified a predominantly germinal center B-cell (GCB) phenotype in  $\sim 60\%$  of O-DLBCL ( $n = 269$  cases, pooled data from 10 studies).<sup>5,13,15-22</sup> Based on gene-expression profiling (GEP), this finding was confirmed by Li et al,<sup>8</sup> describing a GCB phenotype in 90% ( $n = 155$ ). Nonetheless, a comprehensive molecular characterization of O-DLBCL is currently lacking.

To our knowledge, only 2 studies report genetic data explicitly collected from O-DLBCL. First, a lack of *MYD88* L265P hotspot mutation was observed in O-DLBCLs ( $n = 15$ ).<sup>20</sup> Second, applying a limited targeted next-generation sequencing (tNGS) panel, activating mutations in *NOTCH1* and *KRAS* were identified in PB-DLBCL ( $n = 1$ ).<sup>23</sup> Due to the limited number of studies, relatively small patient cohorts, and absence of comprehensive genetic analyses, knowledge is lacking regarding the genetic constitution of O-DLBCL. This is caused by the rarity of the disease, the difficulty in obtaining sufficient diagnostic tissue, and the inability to attain proper molecular analysis of bone biopsy specimens, as decalcification procedures lead to acquisition of DNA artifacts and complicate interpretation of sequencing results. Consequently, it is unclear whether the various O-DLBCL subentities reflect a separate molecular entity or rather a heterogeneous disease, as commonly assumed for DLBCL, not otherwise specified.<sup>24-28</sup>

Since the introduction of tNGS, evidence of genetic heterogeneity associated with histopathologic and clinical features and anatomical localization of DLBCL, not otherwise specified has increased. Therefore, the revised (2016) WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues<sup>29</sup> recognizes extranodal DLBCL with specific anatomy as separate entities, such as intravascular large B-cell lymphoma, primary cutaneous DLBCL, primary cutaneous DLBCL–leg type, and primary DLBCL of the central nervous system (PCNSL), commonly representing an activated B-cell (ABC)

phenotype.<sup>30-36</sup> Following this paradigm and because of their specific disease presentation and clinical behavior, we hypothesized that PB-DLBCL contains unique molecular characteristics. To address this theory, our study presents the first comprehensive GEP and targeted deep-sequencing analyses in a well-annotated and relatively large cohort of PB-DLBCL.

## Methods

### Patient characteristics

This retrospective study investigated 103 cases of O-DLBCLs for which sufficient tumor DNA was available and that were not included in our previous studies.<sup>12,19,37-41</sup> Patients were selected through a search of pathology surveys that reported osseous involvement and were diagnosed between 2002 and 2020 at the Leiden University Medical Center (LUMC;  $n = 48$ ), Amsterdam University Medical Center, location AMC ( $n = 11$ ), Erasmus MC Cancer Institute ( $n = 7$ ), or affiliated nonacademic hospitals ( $n = 37$ ). As an expert center for tumors of soft tissue and bone, the LUMC contribution was enriched for O-DLBCLs. Figure 1A presents an overview of included cases.

Formalin-fixed and paraffin-embedded or fresh frozen tissue samples were obtained during diagnostic procedures (supplemental Table 1). Based on different local standard procedures at the time of initial diagnosis, staging was performed with magnetic resonance imaging, computed tomography imaging, or positron emission tomography/computed tomography scanning and reviewed by a radiologist expert (R.R.) to stratify cases according to WHO definitions (supplemental Table 1).<sup>1,2</sup> As a comparator, the study included 63 patients diagnosed between 2006 and 2020 with nonosseous DLBCL as considered by radiologic assessments and a GCB phenotype (NO-DLBCL-GCB) based on the Hans algorithm (Figure 1A). T-cell/histiocyte-rich DLBCL and Burkitt lymphoma were not included. All cases were classified according to Ann Arbor staging and the International Prognostic Index.


This study was performed in accordance with the Dutch Code for Proper Secondary Use of Human Tissue, the local institutional board requirements, and the revised Declaration of Helsinki (2008). It was approved with a waiver of consent by the LUMC's medical ethics committee (B16.048).

### IHC and fluorescence in situ hybridization

Following the latest WHO classification of lymphoid neoplasms,<sup>29</sup> IHC and fluorescence in situ hybridization (FISH) analyses were performed (details are given in the supplemental Methods). Briefly, IHC was accomplished with CD10, BCL6, and MUM1 antibodies for COO classification according to the Hans algorithm.<sup>14</sup> For O-DLBCLs, *MYC*, *BCL2*, and *BCL6* rearrangements were analyzed according to FISH, using break-apart probes, as outlined elsewhere.<sup>42</sup> NO-DLBCL-GCBs were screened for *MYC* rearrangements, and if present, *BCL2* and *BCL6* rearrangements were assessed. Epstein-Barr virus (EBV) status was determined by EBV-encoded RNA in situ hybridization.

### Gene expression profiling

GEP was performed with a NanoString system and an extended custom-made probe set, covering 20 genes of the Lymph2Cx assay for COO classification and an additional 219 genes related to DLBCL (supplemental Methods).<sup>43-47</sup> For COO classification, raw counts obtained by NanoString gene expression analysis were uploaded at



**Figure 1. Overview of included O-DLBCL and NO-DLBCL cohorts and subentities with specific anatomical localizations.** (A) Flowchart of included and analyzed O-DLBCL and NO-DLBCL subentities. A total of 103 DLBCL cases with osseous involvement were subdivided into three O-DLBCL stages, with PB-DLBCL (n = 41), polyostotic-DLBCL (n = 14), and disseminated-DLBCL (n = 48). Of these, 20 cases failed tNGS quality controls (insufficient DNA or high number of deamination variants), and



the Lymphoma/Leukemia Molecular Profiling Project Web site for COO categorization ([https://llmpp.nih.gov/LSO/LYMPHCX/lymphcx\\_predict.cgi](https://llmpp.nih.gov/LSO/LYMPHCX/lymphcx_predict.cgi)).<sup>48</sup> Technical variation of NanoString nCounter results of each sample was removed by using standardization based on the geometric mean of inherent positive controls in the assay. Next, a principal component analysis was performed as a quality control for identification of possible outliers and potential “batch effects” introduced by NanoString cartridges (supplemental Figure 1). Gene-expression data were normalized by using five Lymph2Cx housekeeping genes, and the resulting data were analyzed with RStudio (R-3.6.3, including packages NanoStringNorm-1.2.1, glmnet-3.0-2, factoextra-1.0.6, ComplexHeatmap-2.2.0, dendextend-1.13.4, ggpubr-0.4.0, and scales-1.1.1). All 234 genes (excluding housekeeping genes) were used to identify GEP clusters within O-DLBCLs and NO-DLBCL-GCB.

Two different assays were used to further subdivide GCB into centroblast or centrocyte B cells. In total, the BAGS(2CLINIC) assays consist of 208 genes, overlapping 26 genes of our custom NanoString panel. Thirteen genes of BAGS(2CLINIC) assays, most distinctive between centroblast and centrocyte B cells, were included for further analysis. In addition, another study recently reported a dark zone/light zone (DZ/LZ) spatial signature consisting of 53 genes, overlapping 11 genes with our panel. Both limited [BAGS(2CLINIC) and DZ/LZ spatial signature] assays, with only *MYC* overlapping, were used separately to assign centroblast-like or centrocyte-like phenotypes (supplemental Figure 3).<sup>49-51</sup>

The GEP data reported in this article have been deposited in the Gene Expression Omnibus database (accession number GSE176126) and can also be found in supplemental Table 4.

### Targeted next-generation deep sequencing

After microdissection from deparaffinized 10- $\mu$ m sections (median tumor cells, 70%; range, 20%-90%) (supplemental Table 1), total nucleic acid was isolated with the fully automated Tissue Preparation System (Siemens Healthcare Diagnostics), as previously described.<sup>52</sup> For fresh frozen biopsy specimens, DNA was isolated from 25- $\mu$ m cryosections by using the QIAamp DNA Mini Kit (Qiagen).

The LYMFv1 NGS panel was designed and validated in-house and is an Ion-Torrent–based AmpliSeq panel (Thermo Fisher Scientific; details are provided in the supplemental Methods). The LYMFv1 panel contains 1362 amplicons, subdivided into 2 primer pools, and covers 52 B-cell lymphoma-relevant genes (supplemental Table 2). Briefly, this panel was compiled from a comprehensive review of ~300 articles (until 2018) on frequencies and clinical relevance of aberrations in B-cell lymphomas. The LYMFv1 panel has an overlap of 73% (33 genes) with a proposed consensus tNGS panel for all mature lymphoid malignancies.<sup>53</sup> LYMFv1 libraries were prepared with an Ion Chef System (Thermo Fisher Scientific) or manually. The

resulting libraries were sequenced on an Ion Torrent S5-system (Thermo Fisher Scientific). Sequence reads were aligned to the human reference genome (GRCh37/hg19) using TMAP 5.07 software, with default parameters (<https://github.com/iontorrent/TS>).<sup>54</sup> Variants were called by a Torrent Variant Caller. The average read count was 2634 (range, 137-16 001). Supplemental Table 1 lists average read counts per patient. Minimum thresholds for calling variants were  $\geq 100$  on-target reads and 10% variant allele frequency. Samples were excluded if deep-sequencing data provided an insufficient number of reads or the transition to transversion ratio was  $\geq 5$ , indicating excess formalin fixation artifacts. All variants were annotated in the Geneticist Assistant NGS interpretive Workbench (SoftGenetics), into class 1 (benign), class 2 (likely benign), class 3 (unknown significance), class 4 (likely pathogenic), or class 5 (pathogenic).<sup>55</sup> Class 4 and 5 variants were designated as pathogenic mutations. Also, class 3 variants of unknown pathogenicity were interpreted as pathogenic mutations, in case of a high Combined Annotation Dependent Depletion–PHRED score ( $> 25$ ) and/or a pathogenic prediction from  $\geq 2$  of 4 selected prediction scores (Sift, PolyPhen, the likelihood ratio test, and MutationTaster). Sequencing data obtained for the O-DLBCL and NO-DLBCL-GCB subgroups were mutually compared. In addition, a literature-based cohort of DLBCL-GCB was gathered from 4 large sequencing studies.<sup>24-27</sup> Corresponding supplemental Tables (or Figure 5<sup>24</sup>) reporting COO subtypes and potential pathogenic variants were used to identify mutational frequencies in DLBCL-GCB cases, collecting a total of 651 DLBCL-GCB cases.

### Statistical analysis

Statistical analyses were performed by using RStudio (R-3.6.3, including packages clustertend-1.4, cmprsk-2.2-10, ComplexHeatmap-2.2.0, dendextend-1.13.4, dynpred-0.1.2, factoextra-1.0.6, ggpubr-0.4.0, glmnet-3.0-2, NanoStringNorm-1.2.1, prodlim-2019.11.13, scales-1.1.1, and survival-3.1.11). Hierarchical clustering analysis on GEP data was performed by using Euclidean distance metric and Ward's minimum variance method for cluster formation. A penalized logistic regression model was applied to identify genes most differentially expressed between PB-DLBCL and NO-DLBCL-GCB.<sup>56</sup> This model was based on Elastic Net regression, for which a mixing parameter  $\alpha$  of 0.10 was used. Analysis of variance was applied on GEP data of a selected set of 13 genes of the BAGS(2CLINIC) assay and 11 genes of the DZ/LZ spatial signature. The Fisher exact test or Student *t* test was applied for analyzing categorical or continuous variables among O-DLBCL subgroups and NO-DLBCL-GCB. Progression-free survival (PFS) or OS was defined as date from initial diagnosis to date of progression and/or death by any cause. Patients were administratively censored after 3 years of follow-up or censored at last follow-up when there was no event. The Kaplan-Meier method was used to determine median follow-up time and to construct survival curves, and they were compared with a log-rank

**Figure 1 (continued)** 83 cases attained appropriate sequencing results. In addition, 63 NO-DLBCL-GCB cases were included as a comparator. Furthermore, 63 samples with adequate RNA were sent for NanoString analysis, of which 3 failed analysis. In total, 24 PB-DLBCL, 5 polyostotic-DLBCL, 11 disseminated-DLBCL, and 20 NO-DLBCL-GCB cases were successfully analyzed with the NanoString platform. (B) Radiologic imaging of International Extranodal Lymphoma Study Group staging system with 3 anatomically defined stages: PB-DLBCL, with a single bone lesion with or without regional involvement of lymph nodes; polyostotic lymphoma (polyostotic-DLBCL), with multifocal disease in a single bone or multiple affected bones; and disseminated lymphoma (disseminated-DLBCL) with  $\geq 1$  bone lesion(s) and  $\geq 1$  (extra)nodal localization(s).<sup>2</sup> NO-GCB-DLBCL was defined as nodal, mixed (nodal and extranodal involvement), or only extranodal localization(s), without any osseous involvement. (C) Frequencies of anatomical osseous localizations identified in all 103 O-DLBCL subentities. Other osseous localizations consisted of one calcaneus, cuneiform, metacarpal III, or talus. (D) Frequencies of anatomical nonosseous localizations of 63 NO-DLBCL-GCBs. CNS, central nervous system.

test. In case of a statistically significant  $P$  value ( $<.05$ ), corresponding hazard ratios and 95% confidence intervals (CIs) were calculated with a Cox proportional hazards model.

## Results

### Patient characteristics

O-DLBCL cases were categorized into PB-DLBCL ( $n = 41$ ), polyostotic-DLBCL ( $n = 14$ ), and disseminated-DLBCL ( $n = 48$ ) (Figure 1A-B).<sup>17</sup> Table 1 summarizes clinical characteristics of both O-DLBCL and NO-DLBCL-GCB subentities. Individual radiologic assessments and age-related bone localizations are described in the supplemental Results. Figure 1C-D displays exact anatomical non-osseous localizations. Consistent with previous studies, the mean age at diagnosis for PB-DLBCL and polyostotic-DLBCL was (borderline) significantly lower (53 and 50 years) compared with that for disseminated-DLBCL (62 years;  $P = .020$  and  $P = .068$ , respectively) and NO-DLBCL-GCB (64 years;  $P = .003$  and  $P = .033$ ).<sup>2,6,7</sup> In addition, NO-DLBCL-GCB cases were subdivided into only nodal ( $n = 19$ ), mixed (nodal and extranodal involvement,  $n = 28$ ), or solitary extranodal ( $n = 16$ ) localization. Six extranodal NO-DLBCL-GCB cases were diagnosed with PCNSL, considered as poor-risk advanced disease (Ann Arbor stage IV) and treated with high-dose methotrexate-containing regimens. Most patients ( $n = 150$  [90%]) were treated with curative intent by using rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-based (immune-) polychemotherapy. Five patients died before treatment, and for palliation, 4 patients received local radiotherapy only or rituximab monotherapy. Median follow-up times for patients with O-DLBCL and NO-DLBCL-GCB were 40 and 20 months, respectively.

### Pathological features

Figure 2 displays morphologic examples and immunohistochemical characteristics of O-DLBCL. According to the Hans classification, a GCB phenotype was identified in 74% of O-DLBCL (70 of 94 patients) (supplemental Table 3). Using NanoString/Lymph2Cx, a GCB phenotype was found in 88% of O-DLBCL cases (35 of 40 patients), an “intermediate/unclassifiable” phenotype in 10% ( $n = 4$ ), and an ABC phenotype in 2% ( $n = 1$ ). In addition, NanoString/Lymph2Cx revealed a GCB phenotype in 90% of NO-DLBCL-GCB cases (18 of 20 patients), one ABC phenotype, and one intermediate/unclassifiable phenotype. Overall, the COO concordance between cases with both IHC and NanoString results was 83% (50 of 60 cases).

### Fluorescence in situ hybridization

The majority of O-DLBCL cases (83 of 103) were screened for *MYC/BCL2/BCL6* rearrangements and EBV status (Figure 3A). Due to technical failures, most likely caused by decalcification of bone material, analysis of all 3 rearrangements failed in 40% (33 of 83 cases). Therefore, only a descriptive analysis was performed. Approximately similar frequencies of rearrangements were identified in polyostotic-DLBCL, disseminated-DLBCL, and NO-DLBCL-GCB, largely consistent with occurrences of DLBCL-GCB cases in the literature.<sup>24,27,28,57</sup> Compared with NO-DLBCL-GCB, *MYC/BCL2* rearrangements were observed at relatively low frequencies, whereas *BCL6* rearrangements were more common (4%, 8%, and 31%, respectively) in PB-DLBCL, indicating that only *BCL6* rearrangements

seem to be relevant for PB-DLBCL lymphomagenesis. A “double/triple”-hit makeup characteristic for high-grade B-cell lymphoma was observed in ten NO-DLBCL-GCB cases and three disseminated-DLBCL cases but not in PB-DLBCL or polyostotic-DLBCL cases. IHC *MYC* and *BCL2* status for evaluating double expressors are described in the supplemental Results. No O-DLBCL ( $n = 61$ ) and only three NO-DLBCL-GCB cases were EBV positive. Lack of EBV in these overall GCB subtype DLBCL cases is consistent with previous studies describing the occurrence of EBV-positive DLBCLs mainly (in elderly subjects) with an ABC phenotype.<sup>58</sup>

### Gene expression profiling

Because the NanoString material was limited, GEP was performed on 63 randomly selected cases, of which  $\sim 20$  ng/ $\mu$ L of RNA was available (Figure 1A; supplemental Table 5). After excluding 3 failed measurements and 2 outliers (supplemental Figure 1), clustering of GEP data was performed on 58 cases, representing 23 PB-DLBCL, 5 polyostotic-DLBCL, 11 disseminated-DLBCL, and 19 NO-DLBCL-GCB. Using both fresh frozen and formalin-fixed, paraffin-embedded tissues for GEP analysis did not affect the identified difference between O-DLBCL and NO-DLBCL-GCB (supplemental Figure 1E). This finding is consistent with previous studies showing a high correlation between GEP data obtained from fresh frozen and formalin-fixed, paraffin-embedded tissues.<sup>59-61</sup> Unsupervised hierarchical clustering with GEP data of an extended Lymph2Cx (234 genes) provided 4 different clusters (clusters A-D) (supplemental Figure 2). The most significant difference was found between cluster A, allocating eight PB-DLBCLs and one NO-DLBCL-GCB, and cluster B, with three PB-DLBCLs and 12 NO-DLBCL-GCBs ( $P < .001$ ). Cluster C was a mixture of O-DLBCL subentities and cluster D an agglomeration of O-DLBCL subtypes and NO-DLBCL-GCBs. Disseminated-DLBCL was observed across all 4 clusters, indicating its heterogeneity and wide variety in disease origins of individual cases.

To further differentiate GEP differences between PB-DLBCL and NO-DLBCL-GCB, a penalized logistic regression model was performed, assigning a significant set of 34 genes differentially expressed between PB-DLBCL and NO-DLBCL-GCB. Unsupervised clustering of these differentially expressed genes generated 3 clusters: A, predominantly PB-DLBCLs; B, an agglomeration of O-DLBCL subtypes and NO-DLBCL-GCB; and C, mainly NO-DLBCL-GCBs (Figure 4). In contrast to NO-DLBCL-GCB, PB-DLBCL displayed significantly increased expression ( $P < .001$ ) of immune response genes (*CTLA4* and *CXCL12*) and *HLA-A*, *HLA-C*, *HLA-E*, and *HLA-F*. Elevated expression levels of *ARID1A* and *SMARCA4* (both involved in chromosome organization) and *FOXO1* (a centroblast hallmark) were found in NO-DLBCL-GCB compared with PB-DLBCL.<sup>62-65</sup>

Subsequently, to relatively distinguish between a centroblast-like or centrocyte-like phenotype of PB-DLBCL and NO-DLBCL-GCB cases, both limited BAGS(2CLINIC)-GEP and DZ/LZ spatial signature assays were assessed.<sup>49-51</sup> Expression levels of 8 genes (62%) were significantly different between PB-DLBCL and NO-DLBCL-GCB ( $P \leq .047$ ) (supplemental Figure 3). PB-DLBCL exhibited significantly higher expression of *BCL2A1* and *IL6R* (centrocyte related), whereas NO-DLBCL-GCB exhibited significantly increased expression for *BCL6*, *MME*, *MYBL1*, *FOXO1*, *SMARCA4*, and *TCL1A* (centroblast related). Applying a limited-DZ/LZ spatial signature, 9 genes showed significantly higher expression (*CD3E*, *CD4*,

**Table 1. Patient characteristics of O-DLBCL and NO-DLBCL-GCB**

Characteristic	PB-DLBCL (n = 41)	Polyostotic-DLBCL (n = 14)	Disseminated-DLBCL (n = 48)	Extranodal NO-DLBCL-GCB (n = 16)	Nodal NO-DLBCL-GCB (n = 19)	Mixed NO-DLBCL-GCB (n = 28)
Male sex	24 (59%)	9 (64%)	32 (67%)	10 (63%)	13 (68%)	18 (64%)
Median age (minimum-maximum), y	54 (18-86)	56 (13-73)	63 (30-91)	65 (46-82)	67 (35-84)	63 (44-95)
<b>Ann Arbor stage</b>						
I (X)E	29 (71%)	0 (0%)	0 (0%)	4 (25%)	2 (11%)	0 (0%)
II (X)E	12 (29%)	0 (0%)	3 (6%)	1 (6%)	9 (47%)	8 (29%)
III (E/S)	0 (0%)	0 (0%)	3 (6%)	0 (0%)	8 (42%)	2 (7%)
IV	0 (0%)	14 (100%)	42 (88%)	11 (69%)	0 (0%)	18 (64%)
<b>IPI score</b>						
0-1	26 (63%)	3 (21%)	7 (15%)	6 (38%)	11 (58%)	8 (29%)
2-5	15 (37%)	11 (79%)	41 (85%)	10 (63%)	8 (42%)	20 (71%)
<b>First-line treatment</b>						
R-CHOP +/- adjuvant radiotherapy*	35 (85%)	12 (86%)	42 (88%)	8 (50%)	16 (84%)	23 (82%)
Other chemotherapy ± adjuvant radiotherapy†	4 (10%)	2 (14%)	4 (8%)	0 (0%)	1 (5%)	3 (11%)
High-dose MTX‡ ± adjuvant radiotherapy	0 (0%)	0 (0%)	0 (0%)	7 (44%)	0 (0%)	0 (0%)
Palliative treatment§	2 (5%)	0 (0%)	2 (4%)	1 (6%)	2 (11%)	2 (7%)
<b>Response to first-line treatment</b>						
CR	37 (90%)	14 (100%)	36 (75%)	11 (69%)	14 (74%)	18 (64%)
Non-CR	4 (10%)	0 (0%)	12 (25%)	5 (31%)	5 (26%)	10 (36%)
Median follow-up, mo	50	53	37	33	17	22

CR, complete response; IPI, International Prognostic Index.


\*R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; n = 136) and adjuvant radiotherapy (n = 47).

†CHVP/BV (cyclophosphamide, doxorubicin, temiposide, and prednisone with bleomycin and vincristine at mid-interval; n = 4), CHOP (n = 1), COPADM (cyclophosphamide, vincristine, prednisone, doxorubicin, and methotrexate; n = 1), DA-EPOCH-R (dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and rituximab; n = 5), PECC (prednisone, etoposide, chlorambucil, and lomustine; n = 1), RCEOP (rituximab, cyclophosphamide, etoposide, vincristine, and prednisone; n = 1), RCVP (rituximab, cyclophosphamide, vincristine, prednisone; n = 1), and adjuvant radiotherapy (n = 9).

‡MATRix (high-dose methotrexate [MTX], cytarabine, thiotepa, and rituximab)/BCNU (Carmustine)/autologous stem cell transplantation (n = 1), MBVP (high-dose MTX, BCNU, temiposide, and prednisone)/HD\_arac (high-dose arabinoside) (n = 1), or RMP (rituximab, high-dose MTX, and procarbazine; n = 5), and adjuvant radiotherapy (n = 2).

§Local radiotherapy (n = 3), Rituximab-monotherapy (n = 1), or no treatment (n = 5).





**Figure 2. Morphologic and immunohistochemical features of O-DLBCLs.** (A) Infiltration of pleomorphic B cells with entrapment of preexisting bone (black arrowhead) in an example of PB-DLBCL. (B) Pleomorphic B cells in a case of PB-DLBCL with large and irregular nuclei with a cleaved, multilobulated appearance and small nucleoli. (C) Pleomorphic B cells in a case of disseminated-DLBCL with large nuclei and prominent large nucleoli with an immunoblastic/plasmablastic appearance. (D) Diffuse staining of CD20 in PB-DLBCL. (E) Diffuse staining of CD10 in an example of PB-DLBCL with a GCB phenotype, according to the Hans algorithm. (F) Strong diffuse staining of MUM1 in an example of disseminated-DLBCL with an ABC phenotype.

*CD8A*, *CTLA4*, *FAS*, *HLA-E*, *ITGB2*, *LAG3*, and *STAT1*) for PB-DLBCL compared with NO-DLBCL-GCB ( $P \leq .031$ ) (supplemental Figure 3C-D), designating a centrocyte-like phenotype for PB-DLBCL. Despite these limited-BAGS(2CLINIC) and limited-DZ/LZ spatial signature analyses, both independently identified GEP differences indicating a possible centrocyte-like phenotype for PB-DLBCL and a conceivable centroblast-like constitution for NO-DLBCL-GCB, corroborating previous results by Li et al.<sup>8</sup>


### Targeted next-generation deep sequencing

In total, 83 O-DLBCLs and 63 NO-DLBCL-GCBs successfully underwent deep sequencing. For 20 O-DLBCLs, obtained NGS data were of insufficient quality due to DNA artifacts (Figure 1A). Pathogenic variants were identified in 49 genes (Figure 3A; supplemental Table 5), with a median of 4 mutated genes per individual (range, 0-12). Four known "hotspot" mutations were elucidated: loss-of-function *B2M* p.M1\* and *CD79B*, p.Y196\*, and gain-of-function *EZH2* p.Y646\*


and *MYD88* p.L265P. In contrast to a prior study, our data revealed low frequencies of *MYD88* p.L265P mutation in O-DLBCLs.<sup>20</sup> Based on strict anatomical WHO definitions, the 2 most biologically different DLBCL subentities (PB-DLBCL and NO-GCB-DLBCL) were compared to explore potential differences. The mutational profile of PB-DLBCL included frequent mutations ( $\geq 25\%$ ) in *B2M*, *EZH2*<sup>Y646\*</sup>, *IRF8*, and *TNFRSF14* (loss-of-function) and differed significantly from NO-DLBCL-GCB, which was relatively lacking these mutations ( $P = .031$ ,  $P = .010$ ,  $P = .047$ , and  $P = .003$ , respectively) (Figure 3C).

In contrast to PB-DLBCL, high occurrences ( $\geq 25\%$ ) of *KMT2D* and *TP53* aberrations were observed within NO-DLBCL-GCB ( $P = .347$  and  $P = .325$ ). In addition to frequent mutations in *CREBBP*, *KMT2D*, *MYD88*, and *TNFRSF14*, *CARD11* was the most commonly mutated gene (36%) in polyostotic-DLBCL and was (borderline) significantly higher compared with PB-DLBCL ( $P = .085$ ), disseminated-DLBCL ( $P = .036$ ), or NO-DLBCL-GCB ( $P = .014$ ), suggesting a biologically






**Figure 3. Significant differences in genetic landscapes between PB-DLBCL and NO-DLBCL-GCB.** OncoPrint plot of the genetic aberrations and COO of O-DLBCL (A) and NO-DLBCL-GCB (B) subentities. COO phenotype is indicated by blue for ABC, orange for GCB, brown for intermediate (only NanoString), and gray for cases with unknown COO phenotype. Furthermore, a positive ISH (FISH or EBV-encoded small RNA) and a mutation in one of the genes are marked with green. Hotspot mutations are indicated with dark red ( $B2M^{M1*}$ ,  $CD79B^{Y196*}$ ,  $EZH2^{Y646*}$ , and  $MYD88^{L265P}$ ). (C) Comparison of identified genetic aberrations with high frequencies ( $\geq 20\%$ ) of PB-DLBCL, NO-DLBCL-GCB, and a pooled literature-based DLBCL-GCB cohort. PB-DLBCL showed a unique genetic profile, with increased frequencies of  $B2M$ ,  $EZH2$ ,  $IRF8$ , and  $TNFRSF14$ , and was significantly different ( $P = .031$ ,  $P = .010$ ,  $P = .047$ , and  $P = .003$ , respectively) compared with NO-DLBCL-GCB harboring high occurrences (although not significant) of  $KMT2D$  and  $TP53$  aberrations ( $P = .347$  and  $P = .325$ ). Except for  $EZH2$  and  $TNFRSF14$  ( $P = .148$  and  $P = .136$ ), the occurrence of mutations in  $B2M$  and  $IRF8$  in our cohort of PB-DLBCL was significantly higher compared with that of the literature-based DLBCL-GCB cohort ( $P = .012$  and  $P = .020$ ). Careful interpretation is needed, as essential data regarding exact anatomical localizations (eg, osseous involvement was unknown) were lacking for these studies. Significant difference ( $P < .05$ ) between two groups were marked with asterisks.



**Figure 4. Specific GEP patterns for PB-DLBCL and NO-DLBCL-GCB.** (A) A penalized logistic regression model assigned 34 differentially expressed genes between PB-DLBCL and NO-DLBCL-GCB. As shown in the heatmap, unsupervised hierarchical clustering of these differentially expressed genes generated 3 clusters: a cluster with predominant PB-DLBCLs, a cluster with an agglomeration of O-DLBCL subentities and NO-DLBCL-GCB, and a cluster with mainly NO-DLBCL-GCBs. In contrast to NO-DLBCL-GCB, PB-DLBCL exhibited significantly ( $P < .001$ ) increased expression of immune response genes (*CTLA4*, *CXCL12*, *HLA-A*, *HLA-C*, *HLA-E*, and *HLA-F*). Elevated expressions of *ARID1A* and *SMARCA4* (both involved in chromosome organization) and *FOXO1* (a centroblast hallmark) were found in NO-DLBCL-GCBs, as opposed to low expressions in PB-DLBCLs. (B) This bar chart shows the distribution of the PB-DLBCL and NO-DLBCL-GCB subentities across elucidated clusters.

distinct subgroup. With frequent mutations in *TNFRSF14*, *KMT2D*, or *TP53*, disseminated-DLBCL exhibited similarities with molecular constitutions of both PB-DLBCL and NO-DLBCL-GCB. In addition, focusing on 19 disseminated-DLBCL cases with bulky osseous

disease (Figure 3), comparable mutational profiles as PB-DLBCL were identified with high frequencies of mutations in *B2M* (16%), *EZH2* (26%), *IRF8* (21%), and *TNFRSF14* (42%), suggesting that this lymphoma originated in bone.



**Figure 5. Three-year PFS and OS analysis for O-DLBCL and NO-DLBCL-GCB subentities.** (A-B) Consistent with the prognostic importance of International Extranodal Lymphoma Study Group staging, PB-DLBCL and polyostotic-DLBCL displayed a significantly superior PFS and OS, compared with disseminated-DLBCL. (C-D) No significant difference in PFS or OS was shown for the subdivision of NO-DLBCL-GCB into extranodal, nodal, and mixed groups. (E-F) PB-DLBCL elucidated a significantly favorable PFS and OS, compared with equivalent Ann Arbor stage I/II NO-DLBCL-GCBs. (G-H) With respect to Ann Arbor stage III/IV, there was no difference in PFS or OS between disseminated-DLBCL and NO-DLBCL-GCB, although polyostotic-DLBCL showed improved survival.



## Survival analyses

Consistent with the prognostic importance of International Extranodal Lymphoma Study Group staging,<sup>2</sup> PB-DLBCL and polyostotic-DLBCL showed superior PFS/OS ( $P = .011/P = .042$ ) (Figure 5A-B), compared with disseminated-DLBCL, with 3-year OS rates of 91% (95% CI, 0.83-1.00), 100% (95% CI, 1.00-1.00), and 77% (95% CI, 0.64-0.90), respectively. No significant difference in PFS/OS was observed for extranodal, nodal, and mixed NO-DLBCL-GCB subentities (Figure 5C-D). PB-DLBCL exhibited a significantly superior PFS/OS compared with equivalent Ann Arbor stage I/II NO-DLBCL-GCBs ( $P = .016/P = .046$ ) (Figure 5E-F). Between PB-DLBCL and NO-DLBCL-GCB, the mutational landscape differed significantly ( $P = .002$ ), as the majority of PB-DLBCLs (24 of 34) harbored  $\geq 1$  mutation in *B2M*, *EZH2*, *IRF8*, and *TNFRSF14*, compared with a minority of stage I/II NO-DLBCL-GCB (7 of 25) with  $\geq 1$  of these specific mutations. No difference was observed in the occurrence of mutations in *KMT2D* or *TP53* between PB-DLBCL (12 of 34) and NO-DLBCL-GCB (12 of 25;  $P = .423$ ). With respect to Ann Arbor stage III/IV, disseminated-DLBCL and NO-DLBCL-GCB exhibited similar survival outcomes, although polyostotic-DLBCL reported an improved PFS/OS (Figure 5G-H). Besides a prognostic impact for Ann Arbor stage, International Prognostic Index, and age, further univariate survival analyses revealed no remarkable survival differences for patient characteristics, COO, rearrangements, or individual pathogenic variants, presumably due to low patient numbers and the relatively low number of events (supplemental Table 6).


## Discussion

To our knowledge, this study is the first to provide a comprehensive and integrative evaluation of IHC, GEP, and targeted deep sequencing in a clinically well-annotated and relatively large cohort of patients with O-DLBCL. As previously described,<sup>9</sup> IHC/NanoString analysis confirmed a predominant GCB phenotype in O-DLBCL cases, across all subentities. Extended-Lymph2Cx-GEP analysis revealed significantly different clusters for PB-DLBCL specifically targeting immune surveillance genes, in contrast to NO-DLBCL-GCB with a focus on chromosome organization and reduction of p53 activity. Limited-BAGS(2CLINIC) and DZ/LZ spatial signature analysis indicated a centrocyte-like phenotype for PB-DLBCL with a preferential origin in the early LZ of B-cell development, as opposed to a centroblast-like constitution (DZ) for NO-DLBCL-GCB. Intriguingly, the predominant GCB centrocyte-like phenotype in PB-DLBCL was supported by frequent mutations in GCB-associated genes (ie, *B2M*, *EZH2*, *IRF8*, *TNFRSF14*). In addition, although with a favorable survival in general for DLBCL-GCB, PB-DLBCL with its corresponding specific mutational profile was significantly associated with a superior OS compared with equivalent Ann Arbor limited-stage I/II NO-DLBCL-GCB. Based on our data, we propose a model in which PB-DLBCL can be recognized as a distinct extranodal DLBCL, with a centrocyte-like GCB phenotype, overexpression of immune response genes, and a unique GCB-associated molecular constitution, thereby reflecting a favorable prognosis (Figure 6).

Controversial O-DLBCL definitions complicate a meaningful comparison between individual studies, including small numbers of O-DLBCL cases ( $n = 4-63$ ) and varying frequencies (25%-86%) of IHC-based GCB phenotypes.<sup>5,13,15-21,66</sup> Using the Affymetrix GeneChip/BAGS2CLINIC assay, Li et al<sup>9</sup> reported a GCB phenotype in 90% of O-DLBCLs ( $n = 155$ ) and a centrocyte-like phenotype in a small

subgroup ( $n = 11$ ). Likewise, our extended-NanoString/Lymph2Cx-GEP showed significantly different GEP clusters for PB-DLBCL and NO-DLBCL-GCB. Also, limited-BAGS(2CLINIC) and DZ/LZ spatial signature analysis indicated a centrocyte-like phenotype for PB-DLBCL and a centroblast-like constitution for NO-DLBCL-GCB.<sup>49-51</sup> In PB-DLBCL, Li et al.<sup>9</sup> reported upregulation of major histocompatibility complex class I, extracellular matrix and adhesion, and tumor suppressor genes and downregulation of pro-oncogenes, compared with NO-DLBCL-GCB. Furthermore, high expression of genes involved in the immune response (*CTLA4* and *CXCL12*) was identified in PB-DLBCL, and together with frequent mutations in *B2M* and *TNFRSF14*, they are important for immune surveillance. This suggests that evasion from immune surveillance is crucial for PB-DLBCL to survive in their osseous environment.<sup>62,63,65,67-69</sup> In contrast, NO-DLBCL-GCB exhibited higher expression of *ARID1A* and *SMARCA4* (chromosome organization through SWI/SNF complex), and both target *TP53* (DNA damage response) and *CDKN1A* (cell cycle inhibitor).<sup>64,65,69</sup> The frequent mutations in genes involved in epigenetics (*CREBBP* and *MEF2B*) and *TP53* mutations indicate that, unlike immune evasion in PB-DLBCL, survival of NO-DLBCL-GCB is critically dependent on deregulation of chromosome organization and reduction of p53 activity.<sup>65,69</sup> Increased expression of *BCL2A1* and *IL6R* indicated a centrocyte-like phenotype for PB-DLBCL. Upregulation of *BCL6*, *MME*, *MYBL1*, *SMARCA4*, and *TCL1A* suggested a centroblast-like constitution for NO-DLBCL-GCB. Lastly, high expression of *FOXO1*, a centroblast hallmark and imperative for sustaining the GC DZ, was specifically found in NO-DLBCL-GCB, thereby supporting a centroblast-like phenotype for NO-DLBCL-GCB, as opposed to low/average *FOXO1* expression in PB-DLBCL.

Comprehensive reviews by Pasqualucci<sup>65</sup> and Mlynarczyk et al.<sup>69</sup> independently provide an integral insight into the development of GCB lymphomas. Following these established pathogenic principles, the frequently mutated GCB-associated genes, *B2M*, *EZH2*, *IRF8*, and *TNFRSF14* ( $\geq 1$  present in 68% of PB-DLBCLs), are likely to play a crucial role in GCB lymphomagenesis, as elucidated by our data. Frequent occurrence of mutations in chromatin modifiers and immunomodulators (e.g. *EZH2* and *TNFRSF14*) was observed, and although there are similarities with follicular lymphoma, other genetic abnormalities such as *BCL2* translocations were less common in PB-DLBCL (2 of 25). Approximately one-quarter of PB-DLBCL pertained a gain-of-function *EZH2* hotspot mutation (Y646\*), which abrogates the terminal B-cell differentiation and cell cycle control.<sup>70</sup> *EZH2* acts as an important GC regulator like *BCL6*, through silencing of genes by tri-methylation of lysine-27 of histone-3 within the PRC2 complex. As such, *EZH2* Y646\* hyper-represses *CKDN1A* and *IRF4*, increasing proliferation and preventing differentiation toward an activated B cell.<sup>65</sup> Consequently, compared with *EZH2* wild-type, *EZH2*-mutated DLBCL seems to be susceptible to tazemetostat (*EZH2* inhibitor).<sup>69,71</sup> Moreover, *B2M* loss-of-function, *EZH2* gain-of-function aberrations, and downregulation of major histocompatibility complex class I/II will lead to a successful evasion of immune surveillance mechanisms.<sup>65,69,72,73</sup> *TNFRSF14* loss-of-function mutations are associated with B- and T-lymphocyte attenuator downregulation, thereby initiating a B-cell autonomous activation and lymphoma-supportive microenvironment.<sup>69,74,75</sup> Finally, *IRF8* is a member of the interferon family of transcription factors, regulating immune response through *BCL6* activation. However, an *IRF8*-driven phenotype alone is insufficient for lymphomagenesis because a second genetic hit is required.<sup>76,77</sup> This is consistent with our findings



**Figure 6. Mechanical overview of GCB development related to PB-DLBCL and NO-DLBCL-GCB and their identified specific GEP patterns and molecular profiles.** As described by Li et al.,<sup>8</sup> and corresponding with our GEP analysis showing an increased expression of *BCL2A1* and *IL6R*, PB-DLBCL preferentially originated in the GC early LZ of B-cell development, indicating a centrocyte-like phenotype. The predominant centrocyte-like GCB phenotype in PB-DLBCL was subsequently supported by frequently mutated GCB-associated genes, such as *B2M*, *EZH2*, *IRF8*, and *TNFRSF14*, culminating in superior survival. In addition, PB-DLBCL exhibited significantly ( $P < .001$ ) increased expression of immune response genes (*CTLA4* and *CXCL12*), and together with frequent mutations in *B2M* and *TNFRSF14*, they are important for immune surveillance, suggesting that evasion from immune surveillance is crucial for PB-DLBCL to survive in their osseous environment. In contrast, upregulation of *BCL6*, *MME*, *MYBL1*, *SMARCA4*, and *TCL1A* suggested a centroblast-like constitution for NO-DLBCL-GCB. Accordingly, high expression of *FOXO1*, a centroblast hallmark and imperative for sustaining the GC DZ,<sup>62-65,69</sup> was specifically identified in NO-DLBCL-GCB. Furthermore, elevated expression levels of *ARID1A* and *SMARCA4* (both involved in chromosome organization) were found in NO-DLBCL-GCB. Together with frequent mutations in genes involved in epigenetics (*CREBBP* and *MEF2B*) and *TP53* mutations, this indicates that, unlike immune evasion in PB-DLBCL, survival of NO-DLBCL-GCB is critically dependent on deregulation of chromosome organization and reduction of p53 activity. Our results thus emphasize that PB-DLBCL can be recognized as a distinct extranodal DLBCL, with a GCB-centrocyte-like phenotype, a specific GEP pattern, and a unique GCB-associated molecular constitution, reflecting favorable prognosis. Purple color indicates genes related to a centroblast-like phenotype, whereas brown-colored genes are related to a centrocyte-like phenotype.

indicating that 57% (12 of 21) of mutated *IRF8* cases were accompanied by  $\geq 1$  *B2M*, *EZH2*, and/or *TNFRSF14* abnormalities.

Four NGS studies investigated the mutational landscape of large DLBCL cohorts and also reported on COO (Affymetrix, IHC, and/or NanoString), allowing direct comparison of mutation frequencies in COO-stratified subgroups vs our results in O-DLBCL.<sup>24-27</sup> These studies included 96, 60, 331, and 164 DLBCL-GCB cases, respectively. This pooled literature-based DLBCL-GCB cohort ( $n = 651$ ) yields mutation frequencies for *B2M*, *EZH2*, *IRF8*, *KMT2D*, *TNFRSF14*, and *TP53* of 15%, 16%, 14%, 32%, 21%, and 15%, respectively (Figure 3C). Except for *EZH2* and *TNFRSF14* ( $P = .148$  and  $P = .136$ ), the occurrence of mutations in *B2M* and *IRF8* in our cohort of PB-DLBCL was significantly higher compared with the literature-based DLBCL-GCB cohort ( $P = .012$ , and  $P = .020$ ). Because essential data regarding exact anatomical localizations (with osseous involvement unknown) were lacking for these studies, and control for confounding factors was not possible, it could be assumed that a proportion of DLBCL-GCBs were PB-DLBCLs. Excluding these cases from this literature-based cohort might increase the significance level of this comparison. Although an independent validation study remains indispensable, this external literature-based assessment strengthens our findings by emphasizing that PB-DLBCL could be recognized as a distinct molecular entity characterized by frequent mutations in *B2M*, *EZH2*, *IRF8*, and *TNFRSF14*, compared with NO-DLBCL-GCB.

Clustering analyses in the noted NGS studies have independently designated different (and partially overlapping) molecular DLBCL subtypes related to COO, prognosis, and potential therapeutic targets. In the current study, the limited tNGS panel used for sequencing and lack of chromosomal aberrations impaired proper molecular classification of O-DLBCL subtypes. As such, supplemental Table 7 summarizes only a derivative of these clusters related to molecular profiles identified in O-DLBCL subentities. Considering frequent mutations in *B2M*, *EZH2*, *IRF8*, and *TNFRSF14*, PB-DLBCL could primarily be categorized in “good-risk” clusters (eg, C1, C3, EZB, BN2, BCL2), which corroborates our results that PB-DLBCL is associated with favorable survival. This contrasts with other WHO-recognized extranodal DLBCLs, such as PCNSL, primary cutaneous DLBCL–leg therapy, and intravascular large B-cell lymphoma, which are primarily characterized by ABC phenotypes and inferior survival. Our findings in PB-DLBCL coincide with compelling evidence, illustrating superior OS for DLBCL-GCB compared with DLBCL-ABC.<sup>2,30-36</sup>

The characterized genetic background of PB-DLBCL does not answer the question of whether a lymphoma originates in the bone, as it is assumed that a GC does not exist in bones, or that circulating lymphoma cells are attracted by locally secreted chemokines. The contrast in mutational profiles between PB-DLBCL and NO-DLBCL-GCB (and even more with opposite extranodal DLBCL-ABCs) requires additional investigation into the coherence of these genetic factors and the resulting specific interactions with its microenvironment. Remarkably, no specific (extranodal) DLBCL-GCB entity has yet been recognized in the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, and therefore this study can be used as a reference study for DLBCL-GCB. As stated before,<sup>78</sup> our findings (re)affirm the supplementary merit of examining well-annotated homogeneous cohorts and invoke the need for additional in-depth evaluation of extranodal DLBCLs.

This study was limited by a percentage of GEP (7%;  $n = 3$ ) and tNGS (19%;  $n = 20$ ) dropouts of the O-DLBCL cohort, illustrating difficulties in molecular analysis on decalcified bone tissue, with no indication that this dropout is selective for certain outcomes. By using IHC as the primary COO classifier, several non-GCB IHC cases that harbor a late GCB phenotype are absent from our comparator NO-DLBCL-GCB cohort. Given the low percentage (9%) of dissimilar COO classification by IHC and NanoString in the original study,<sup>48</sup> we anticipate that this may have possibly biased our results but to a limited extent. Moreover, this investigation would have benefited from more extensive GEP measurements (eg, complete BAGS2CLINIC assay or DZ/LZ spatial signature assay) for refinement of COO clustering and comprehensive sequencing data (eg, whole-exome sequencing) to elucidate complete molecular profiles, including copy number alterations or larger structural variations. Nevertheless, these techniques would also have been impeded by our perceived (partially) suboptimal DNA/RNA qualities. Furthermore, GEP analyses focused on the comparison of PB-DLBCL with NO-DLBCL-GCB, and therefore the numbers of polyostotic-DLBCL and disseminated-DLBCL analyzed were underrepresented and require additional research. A sensitivity analysis showed that the inclusion of a relatively small number of high-grade B-cell lymphoma cases did not significantly bias our results (supplemental Results). Multivariate analyses showed that the heterogeneity in age, chemotherapy, or adjuvant radiotherapy did not confound our survival outcomes.

In conclusion, this study is the first to show that PB-DLBCL is characterized by a centrocyte-like GCB phenotype, with a specific GEP pattern and GCB-associated mutational profile (mainly *B2M*, *EZH2*, *IRF8*, and *TNFRSF14* mutations), both involved in immune surveillance, and is associated with favorable survival. Consequently, these new biological findings provide evidence that PB-DLBCL can be recognized as a distinct extranodal DLBCL entity and offers potential for the development of targeted therapies (eg, *EZH2* inhibitors or other epigenetic-modulating agents<sup>69</sup>) to ultimately improve patients' survival.

## Acknowledgments

The authors thank A. Stolk, D. van Egmond, E. de Winter, J. Neefjes, M. Suleiman Ibramoglu, and S. Somers for their valuable technical assistance. They acknowledge the support provided by Louis M. Staudt's Laboratory at the National Cancer Institute of the National Institutes of Health for the online analysis of Lymph2Cx raw data for COO characterization.

This study is funded by the Stichting Fonds Oncologie Holland.

## Authorship

Contribution: Histopathologic samples were provided by P.M.J., V.T., A.N., I.F.-S., W.C.E.d.H., P.C.W.H., S.T.P., A.D., J.V.M.G.B., and A.H.G.C.; pathology review was performed by P.M.J., V.T., A.N., I.F.-S., W.C.E.d.H., P.C.W.H., S.T.P., A.D., J.V.M.G.B., and A.H.G.C.; R.A.L.d.G., R.v.E., T.v.W., D.R., F.A.d.G., K.K., and I.B.-d.B. gathered data derived from tNGS and FISH; GEP with the NanoString and Lymph2Cx data analysis was provided by A.v.d.B. and A.D.; R.R. performed radiologic review; clinical data regarding patients with NO-DLBCL from other hospitals were provided by L.t.B., H.L., L.H., F.A.d.G. L.H.B., E.F.M.P., M.N., P.J.L., M.J.K., and H.V.; statistical analyses was performed by R.A.L.d.G., S.B., A.H.G.C., and J.S.P.V.; and



R.A.L.d.G., A.H.G.C., and J.S.P.V. wrote the manuscript and all authors approved the final manuscript.

Conflict-of-interest disclosure: M.J.K. has received honoraria/research funding from Kite Pharma, Millennium/Takeda, Mundipharma, Gilead Sciences, Bristol Myers Squibb, Roche, Celgene, Novartis Pharmaceuticals Corporation, and Amgen. P.J.L. has received honoraria/research funding from Takeda, Servier, Genmab, Roche, Genentech, Celgene, Incyte, and Regeneron. The remaining authors declare no competing financial interests.

ORCID profiles: S.B., 0000-0001-9108-9212; T.van W., 0000-0001-5773-7730; D.R., 0000-0002-8231-3398; P.C.W.H., 0000-0002-1513-8104; A.van den B., 0000-0002-8894-2638; A.D.,

0000-0001-9239-1050; M.N., 0000-0002-2740-2873; P.J.L., 0000-0002-6735-8651; J.V.M.G.B.ée, 0000-0003-1155-0481; J.S.P.V., 0000-0002-1628-6256; R. AL de G. 0000-0002-2998-2066; R. van E. 0000-0001-7955-6295; P.M.J. 0000-0002-2361-9303; I.B.-de B. 0000-0002-9273-2828; F.A de G. 0000-0001-9940-2891; V.T. 0000-0002-1354-6307; E.F.M.P. 0000-0002-0882-2346; I.F.-S. 0000-0001-6991-9291; M.J.K. 0000-0002-8904-3802; S.T.P. 0000-0002-1419-0939; H.V. 0000-0002-9108-3125; A.H.G.C. 0000-0002-3672-4348.

Correspondence: Joost S.P. Vermaat, Department of Hematology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands; e-mail: j.s.p.vermaat@lumc.nl.

## References

1. Cleven AHG, Ferry JA. Primary non-Hodgkin lymphoma of bone. In: WHO Classification of Tumours Editorial Board, ed. WHO Classification of Tumours, 5th Edition, Volume 3: Soft Tissue and Bone Tumours. Lyon, France: IARC; 2020:489.
2. Messina C, Christie D, Zucca E, Gospodarowicz M, Ferreri AJ. Primary and secondary bone lymphomas. *Cancer Treat Rev*. 2015;41(3):235-246.
3. Jawad MU, Schneiderbauer MM, Min ES, Cheung MC, Koniaris LG, Scully SP. Primary lymphoma of bone in adult patients. *Cancer*. 2010;116(4):871-879.
4. Pellegrini C, Gandolfi L, Quirini F, et al. Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients. *Clin Lymphoma Myeloma Leuk*. 2011;11(4):321-325.
5. Wu H, Bui MM, Leston DG, et al. Clinical characteristics and prognostic factors of bone lymphomas: focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas. *BMC Cancer*. 2014;14(1):900.
6. Bruno Ventre M, Ferreri AJ, Gospodarowicz M, et al; International Extranodal Lymphoma Study Group. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). *Oncologist*. 2014;19(3):291-298.
7. Tao R, Allen PK, Rodriguez A, et al. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. *Int J Radiat Oncol Biol Phys*. 2015;92(1):122-129.
8. Li X, Xu-Monette ZY, Yi S, et al. Primary bone lymphoma exhibits a favorable prognosis and distinct gene expression signatures resembling diffuse large B-cell lymphoma derived from centrocytes in the germinal center. *Am J Surg Pathol*. 2017;41(10):1309-1321.
9. Cleven AHG, Hogendoorn PCW. Hematopoietic tumors primarily presenting in bone. *Surg Pathol Clin*. 2017;10(3):675-691.
10. Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. *Cancer*. 2006;106(12):2652-2656.
11. Santos TMD, Zumárraga JP, Reaes FM, Maçaneiro CH, Baptista AM, Camargo OP. Primary bone lymphomas: retrospective analysis of 42 consecutive cases. *Acta Ortop Bras*. 2018;26(2):103-107.
12. Heyning FH, Hogendoorn PC, Kramer MH, Holland CT, Dreef E, Jansen PM. Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype. *J Clin Pathol*. 2009;62(9):820-824.
13. de Leval L, Braaten KM, Ancukiewicz M, et al. Diffuse large B-cell lymphoma of bone: an analysis of differentiation-associated antigens with clinical correlation. *Am J Surg Pathol*. 2003;27(9):1269-1277.
14. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*. 2004;103(1):275-282.
15. Bhagavathi S, Micale MA, Les K, Wilson JD, Wiggins ML, Fu K. Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature. *Am J Surg Pathol*. 2009;33(10):1463-1469.
16. Lima FP, Bousquet M, Gomez-Brouchet A, et al. Primary diffuse large B-cell lymphoma of bone displays preferential rearrangements of the c-MYC or BCL2 gene. *Am J Clin Pathol*. 2008;129(5):723-726.
17. Chisholm KM, Ohgami RS, Tan B, Hasserjian RP, Weinberg OK. Primary lymphoma of bone in the pediatric and young adult population. *Hum Pathol*. 2017;60:1-10.
18. Hayase E, Kurosawa M, Suzuki H, et al. Primary bone lymphoma: a clinical analysis of 17 patients in a single institution. *Acta Haematol*. 2015;134(2):80-85.
19. Koens L, Heyning FH, Szepesi A, Matolcsy A, Hogendoorn PC, Jansen PM. Nuclear factor-kappaB activation in primary lymphoma of bone. *Virchows Archiv*. 2013;462(3):349-354.
20. Xu Y, Li J, Ouyang J, et al. Prognostic relevance of protein expression, clinical factors, and MYD88 mutation in primary bone lymphoma. *Oncotarget*. 2017;8(39):65609-65619.

21. Zhang X, Zhu J, Song Y, Ping L, Zheng W. Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients. *Sci Rep.* 2016;6(1):28834.
22. Adams H, Tzankov A, d'Hondt S, Jundt G, Dirnhofer S, Went P. Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors. *Hum Pathol.* 2008;39(9):1323-1330.
23. Zaharie F, Pop LA, Petrushev B, et al. Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient. *Histol Histopathol.* 2019;34(6):663-670.
24. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published corrections appear in *Nat Med.* 2018;24(8):1292 and *Nat Med.* 2018;24(8):1290–1291]. *Nat Med.* 2018;24(5):679-690.
25. Karube K, Enjuanes A, Dlouhy I, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. *Leukemia.* 2018;32(3):675-684.
26. Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. *Cell.* 2017;171(2):481-494.e15.
27. Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. *N Engl J Med.* 2018;378(15):1396-1407.
28. Lacy SE, Barrans SL, Beer PA, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. *Blood.* 2020;135(20):1759-1771.
29. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumour of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Lyon, France: IARC Press; 2017
30. Bődör C, Alpár D, Marosvári D, et al. Molecular subtypes and genomic profile of primary central nervous system lymphoma. *J Neuropathol Exp Neurol.* 2020;79(2):176-183.
31. Schrader AMR, Jansen PM, Vermeer MH, Kleiverda JK, Vermaat JSP, Willemze R. High incidence and clinical significance of MYC rearrangements in primary cutaneous diffuse large B-cell lymphoma, leg type. *Am J Surg Pathol.* 2018;42(11):1488-1494.
32. Schrader AMR, Jansen PM, Willemze R, et al. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. *Blood.* 2018;131(18):2086-2089.
33. Vajpayee N, Hussain J, Tolocica I, Hutchison RE, Gajra A. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases. *J Neurooncol.* 2010;100(2):249-253.
34. Camilleri-Broët S, Crinière E, Broët P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. *Blood.* 2006;107(1):190-196.
35. Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. *Cancer Discov.* 2017;7(9):1018-1029.
36. Preusser M, Woehrer A, Koperek O, et al. Primary central nervous system lymphoma: a clinicopathological study of 75 cases. *Pathology.* 2010;42(6):547-552.
37. Hemingway F, Kashima TG, Mahendra G, et al. Smooth muscle actin expression in primary bone tumours. *Virchows Arch.* 2012;460(5):525-534.
38. Rajnai H, Heyning FH, Koens L, et al. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone. *Virchows Archiv.* 2014;464(2):229-239.
39. Heyning FH, Kroon HM, Hogendoorn PC, Taminiou AH, van der Woude HJ. MR imaging characteristics in primary lymphoma of bone with emphasis on non-aggressive appearance. *Skeletal Radiol.* 2007;36(10):937-944.
40. Heyning FH, Jansen PM, Hogendoorn PC, Szuhai K. Array-based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone. *J Clin Pathol.* 2010;63(12):1095-1100.
41. Heyning FH, Hogendoorn PC, Kramer MH, et al. Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases. *Leukemia.* 1999;13(12):2094-2098.
42. Vermaat JS, Somers SF, de Wreede LC, et al. MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavourable prognosis. *Haematologica.* 2020;105(2):424-434.
43. Scott DW, Mottok A, Ennishi D, et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. *J Clin Oncol.* 2015;33(26):2848-2856.
44. Chan FC, Telenius A, Healy S, et al. An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. *Blood.* 2015;125(6):959-966.
45. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. *Blood.* 2005;105(5):1851-1861.
46. Carey CD, Gusenleitner D, Chapuy B, et al. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. *J Mol Diagn.* 2015;17(1):19-30.
47. Keane C, Vari F, Hertzberg M, et al. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. *Lancet Haematol.* 2015;2(10):e445-e455.
48. Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. *Blood.* 2014;123(8):1214-1217.

49. Michaelsen TY, Richter J, Brøndum RF, et al. A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology. *Blood Adv.* 2018;2(13):1542-1546.
50. Dybkær K, Bøgsted M, Falgreen S, et al. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. *J Clin Oncol.* 2015;33(12):1379-1388.
51. Tripodo C, Zanardi F, Iannelli F, et al. A spatially resolved dark- versus light-zone microenvironment signature subdivides germinal center-related aggressive B cell lymphomas. *iScience.* 2020;23(10):101562.
52. van Eijk R, Stevens L, Morreau H, van Wezel T. Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis. *Exp Mol Pathol.* 2013;94(1):121-125.
53. Sujobert P, Le Bris Y, de Leval L, et al. The need for a consensus next-generation sequencing panel for mature lymphoid malignancies. *HemaSphere.* 2018;3(1):e169.
54. Cohen D, Hondelink LM, Solleveld-Westerink N, et al. Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing. *J Thorac Oncol.* 2020;15(6):1000-1014.
55. Thompson BA, Spurdle AB, Plazzer JP, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. *Nat Genet.* 2014;46(2):107-115.
56. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. *J Stat Softw.* 2010;33(1):1-22.
57. Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. *Sci Transl Med.* 2016;8(364):364ra155.
58. Vockerodt M, Vrzalikova K, Ibrahim M, et al. Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma. *J Pathol.* 2019;248(2):142-154.
59. Ragulan C, Eason K, Fontana E, et al. Analytical validation of multiplex biomarker assay to stratify colorectal cancer into molecular subtypes. *Sci Rep.* 2019;9(1):7665.
60. Sun J, Chen DT, Li J, et al. Development of malignancy-risk gene signature assay for predicting breast cancer risk. *J Surg Res.* 2020;245:153-162.
61. Vukmirovic M, Herazo-Maya JD, Blackmon J, et al. Identification and validation of differentially expressed transcripts by RNA-sequencing of formalin-fixed, paraffin-embedded (FFPE) lung tissue from patients with idiopathic pulmonary fibrosis. *BMC Pulm Med.* 2017;17(1):15.
62. Dürr C, Pfeifer D, Claus R, et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. *Cancer Res.* 2010;70(24):10170-10181.
63. Herrmann A, Lahtz C, Nagao T, et al. CTLA4 promotes Tyk2-STAT3-dependent B-cell oncogenicity. *Cancer Res.* 2017;77(18):5118-5128.
64. Lunning MA, Green MR. Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas. *Blood Cancer J.* 2015;5(10):e361.
65. Pasqualucci L. Molecular pathogenesis of germinal center-derived B cell lymphomas. *Immunol Rev.* 2019;288(1):240-261.
66. Shen H, Wei Z, Zhou D, et al. Primary extra-nodal diffuse large B-cell lymphoma: a prognostic analysis of 141 patients. *Oncol Lett.* 2018;16(2):1602-1614.
67. Nijland M, Veenstra RN, Visser L, et al. HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy? *Oncol Immunology.* 2017;6(4):e1295202.
68. Boice M, Salloum D, Mourcin F, et al. Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. *Cell.* 2016;167(2):405-418.e13.
69. Mlynarczyk C, Fontán L, Melnick A. Germinal center-derived lymphomas: the darkest side of humoral immunity. *Immunol Rev.* 2019;288(1):214-239.
70. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. *Nat Genet.* 2010;42(2):181-185.
71. Sarkozy C, Morschhauser F, Dubois S, et al. A LYSA Phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features. *Clin Cancer Res.* 2020;26(13):3145-3153.
72. El Hussein S, Shaw KRM, Vega F. Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers. *Modern Pathol.* 2020;33(12):2422-2436.
73. Challa-Malladi M, Lieu YK, Califano O, et al. Combined genetic inactivation of  $\beta$ 2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. *Cancer Cell.* 2011;20(6):728-740.
74. Steinberg MW, Cheung TC, Ware CF. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. *Immunol Rev.* 2011;244(1):169-187.
75. Ennishi D, Hsi ED, Steidl C, Scott DW. Toward a new molecular taxonomy of diffuse large B-cell lymphoma. *Cancer Discov.* 2020;10(9):1267-1281.
76. Qiu Z, Holder KN, Lin AP, et al. Generation and characterization of the E $\mu$ -Irf8 mouse model. *Cancer Genet.* 2020;245:6-16.
77. Lee CH, Melchers M, Wang H, et al. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. *J Exp Med.* 2006;203(1):63-72.
78. Vermaat JS, Pals ST, Younes A, et al; EHA Lymphoma Group, a Scientific Working Group of the European Hematology Association. Precision medicine in diffuse large B-cell lymphoma: hitting the target. *Haematologica.* 2015;100(8):989-993.